688513 Share Price Performance
CN¥55.34
13.04 (30.83%)
Price CN¥55.34
Share PriceCN¥55.34
Chengdu Easton Biopharmaceuticals Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
688513 Community Narratives
There are no narratives available yet.
Recent 688513 News & Updates
Chengdu Easton Biopharmaceuticals Co., Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 28, 2025
- Earnings per share (EPS)
- 1.32
- Gross Margin
- 73.35%
- Net Profit Margin
- 17.11%
- Debt/Equity Ratio
- 4.6%
Chengdu Easton Biopharmaceuticals Co., Ltd. Competitors
Snowflake Analysis
About 688513
- Founded
- 2009
- Employees
- 1522
- CEO
- WebsiteView website
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricaracetam and Lacosamide for neurological and psychiatric applications; and Empagliflozin for anti-diabetic applications. The company was founded in 2009 and is based in Chengdu, China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 1.8%
- 3 Months: 18.4%
- 1 Year: 24.1%
- Year to Date: 26.2%
In the last week, the market is up 1.8% led by Industrials sector. In the last year, the market has climbed 24%. As for the next few years, earnings are expected to grow by 27% per annum. Market details ›